ALTHEA TECHNOLOGIES INC
- Headquarters
- SAN DIEGO, CA
- Latest Form D
- $553K offered, Jul 2010
- Total capital
- $2M
- Federal grants
- $1.4M
- 7 awards · 2000–2006
- Private capital raised
- $553K
- 1 Form D · last Jul 2010
- 195 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 7 pending
Capital timeline
Latest events
- Offering registeredForm D · SEC · 1st filing$553K
- Federal grantHealth and Human S · Phase I · Practical High Througput Low Cost Gene Expression Analysis$154K
- Federal grantHealth and Human S · R01 · High Throughput PCR-Based Gene Expression Screening$223K
- Federal grantHealth and Human S · R01 · High Throughput PCR-Based Gene Expression Screening$229K
- Federal grantHealth and Human S · Phase I · Validating and Translating Array Signatures$100K
- Federal grantHealth and Human S · Phase I · Validation of Gene Expression Based Toxicity Screening$100K
- Federal grantHealth and Human S · Phase I · Development of a Multiplexed Gene Expression Screen$100K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase II · Comprehensive Gene Expression Profiling For Toxicology$500K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
119months
from ALTHEA TECHNOLOGIES INC’s first federal award to its first private round.
- First federal award · Sep 2000
- Health and Human S · $500K
- First Form D · Jul 2010
- $553K · 1st Form D
- Awards before first raise
- 7 awards
An association in public records, not a cause or a prediction.
Founders and team
Researcher links verified by same-company patents and grants- Francois H. FerreResearcherDirectorLinked by $100K in grants as PI
- Deval A. LashkariDirectorNamed in SEC Form D filings
- James B. GlavinDirectorNamed in SEC Form D filings
- J. Matthew MackowskiDirectorNamed in SEC Form D filings
- Magda T. MarquetDirectorNamed in SEC Form D filings
- Shabbir T. AnikExecutive Officer, DirectorNamed in SEC Form D filings
Show all 7 people
- William Matthew KachioffExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 7- PendingStabilized Protein Crystals, Formulations Containing Them and Methods of Making ThemUSPTOApplication 14021997
- PendingUricase Compositions And Methods Of UseUSPTOApplication PCTUS2009038124
- PendingPredicting Vaccine EfficacyUSPTOApplication PCTUS2008066376
Show all 7 patent records
- Stabilized Protein Crystals, Formulations Containing Them and Methods of Making ThemMar 27, 2014 · Application 14021997Pending
- Uricase Compositions And Methods Of UseApplication PCTUS2009038124Pending
- Predicting Vaccine EfficacyApplication PCTUS2008066376Pending
- Biochemical Analysis Of Partitioned CellsApplication PCTUS2007012727Pending
- Compositions And Methods For The Analysis Of Degraded Nucleic AcidsApplication PCTUS2006017169Pending
- Expression Profiling Using MicroarraysApplication PCTUS2004029749Pending
- Strategies For Gene Expression AnalysisApplication PCTUS2003022217Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .